Clinical Trials Logo

Clinical Trial Summary

Fibroblast Growth Factor 23 and Fibroblast Growth Factor 21 are two endocrine Fibroblast Growth Factors, requiring Klotho as a co-factor to promote their systemic actions. Fibroblast Growth Factor 21 is involved in the regulation of glucid and lipid metabolism. Fibroblast Growth Factor 21 Knock Out mice display obesity and hyperglycemia. In investigators experience, patients with X-linked hypophosphatemia often present with early-onset over-weight that could be partly explained by decreased physical activity because of bone pains and deformations after puberty; however, patients usually display progressive over-weight earlier in life, when there is no limitation of physical activity yet. To the knowledge of investigators the association between Fibroblast Growth Factor 23, Fibroblast Growth Factor 21 and Klotho in patients with X-linked hypophosphatemia has never been evaluated. Thus, the main objective of this study is to evaluate the glucid and lipid metabolism in patients with X-linked hypophosphatemia, the main working hypothesis being that the genetic deregulation in the Fibroblast Growth Factor 23 axis in patients with X-linked hypophosphatemia induces modifications of Klotho levels (namely decreased levels) that in turn will deregulate the Fibroblast Growth Factor 21 axis (resistance to Fibroblast Growth Factor 21 because of decreased Klotho levels).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03596554
Study type Observational
Source Hospices Civils de Lyon
Contact
Status Completed
Phase
Start date January 11, 2019
Completion date February 27, 2020

See also
  Status Clinical Trial Phase
Completed NCT02915705 - Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) Phase 3
Recruiting NCT03879915 - Dental Implants in Patients With X-linked Hypophosphatemia
Active, not recruiting NCT03193476 - Registry for Patients With X-Linked Hypophosphatemia
Completed NCT02526160 - Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Phase 3
Recruiting NCT05181839 - A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
Completed NCT04146935 - Examining the Effect of Burosumab on Muscle Function Phase 4
Completed NCT02750618 - Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Phase 2
Active, not recruiting NCT03745521 - Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Completed NCT03920072 - Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Phase 3
Recruiting NCT03748966 - Calcitriol Monotherapy for X-Linked Hypophosphatemia Early Phase 1
Recruiting NCT04419363 - Burosumab in Children and Adolescents With X-linked Hypophosphatemia Phase 4
Completed NCT02163577 - Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Phase 2
Active, not recruiting NCT03651505 - X-linked Hypophosphatemia Disease Monitoring Program
Completed NCT06067932 - Foot Disorders in X-linked Hypophosphatemia
Completed NCT04695860 - Anti-FGF23 (Burosumab) in Adult Patients With XLH Phase 3
Completed NCT02312687 - Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) Phase 2
Recruiting NCT03820518 - Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia Phase 4
Completed NCT01571596 - An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia Phase 1/Phase 2
Completed NCT04273490 - Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
Completed NCT03489993 - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)